Artelo Biosciences, Inc. (ARTL, Financial) shares experienced a significant uptick, climbing 6.36% to reach $1.17. The trading volume was 19,822 shares with a turnover rate of 0.61% and a price fluctuation of 5.45%.
Recent financials reveal that Artelo Biosciences reported no revenue and a net loss of $2.43 million, equating to a loss of $0.75 per share. The company's gross profit was zero, with a price-to-earnings ratio of -0.34.
All four analysts covering ARTL have issued a buy recommendation, with no analysts suggesting a hold or sell.
The biotechnology sector saw an overall decline of 0.49%. Within the sector, related stocks such as 180 Life Sciences Corp. and Quoin Pharmaceuticals Ltd showed notable gains and trading activity. Key metrics for these stocks include high turnover rates of 7059.86% for 180 Life Sciences Corp. and 1604.70% for Quoin Pharmaceuticals Ltd. They also experienced significant price swings.
Artelo Biosciences is a U.S.-based biopharmaceutical company specializing in the development of therapies targeting lipid signaling pathways, specifically the endocannabinoid system. This system comprises receptors and neurotransmitters forming a biochemical communication network within the body. The company's focus includes discovering, licensing, developing, and commercializing treatments that modulate this system. Artelo's flagship project aims to create a patented cannabinoid drug combination therapy for rare diseases.
